6 May 2014 - Deborah Wilkes
Archived
Merck & Co's application to switch the asthma drug Singulair (montelukast) from prescription-to-OTC status as an allergy remedy has been rejected by advisers to the US Food and Drug Administration (FDA).
New to OTCToolbox?
This is available as part of an Annual Subscription to the OTCToolbox website.